Analysis of the Reentry Test Results of the Deferred Donors with Hepatitis B Surface Antigen Reactivity / 대한수혈학회지

BACKGROUND: Since 2004, the donors showing hepatitis B surface antigen (HBsAg) reactive results have been registered in the donor deferral registry (DDR). Some of them can donate blood as eligible donors by passing the reentry tests. We evaluated the results of the reentry tests during 1 year. METHODS: We tested the samples from 2,230 deferred donors with HBsAg reactivity and 1,668 samples from donors who had a past history of hepatitis B and all these patients required reentry tests. Hepatitis B surface antigen, hepatitis B core antibody and hepatitis B surface antibody were tested for by using ARCHITECT HBsAg (Abbott, Wiesbaden, Germany), ARCHITECT anti-HBc (Abbott), and ARCHITECT anti-HBs (Abbott) and using an ARCHITECT i2000SR (Abbott). Hepatitis B virus DNA was tested for by performing HBV Polymerase Chain Reaction (PCR) with a COBAS AMPLICOR HBV MONITOR TEST (Roche Molecular Systems Inc., Branchburg, USA) and using a COBAS AMPLICOR (Roche Diagnostics, Basel, Switzerland). RESULTS: 894 (40.1%) of 2,230 the deferred donors and 880 (52.8%) of 1,668 donors who had a past history of hepatitis B were reentered as eligible donors. 1,171 (30.0%) of the 3,898 tested donors couldn't be released due to positive results on the anti-HBc test and 81.5% of them were also anti-HBs positive. CONCLUSION: The reentry test seems to be necessary to restore blood donors. But it was considered that the donor showing a reactive result for anti-HBc and a nonreactive result for HBsAg and HBV PCR can be released as eligible donors if the anti-HBs titer is higher than the reference value.

Prognostic factors of cervical cancer stage IB2 treated surgically / 대한산부인과학회지

OBJECTIVE: This study was performed to identify pathologic and clinical risk factors that predicted survival in cervical cancer stage IB2 patients treated surgically. METHODS: The records of 52 patients with cervical cancer IB2 who underwent radical hysterectomy with pelvic lymph node dissection from 1997 to 2003 were reviewed retrospectively. Clinical and pathologic variables included age, tumor size (TS), histologic type, involvement of resection margin, parametrium invasion, lymph node metastasis (LN), lymph-vascular space invasion, depth of invasion, treatment modality and adjuvant radiation therapy (RTx). Survival analyses were performed by the Kaplan-Meier curves and the log-rank test. Independent prognostic factors were determined by Cox's proportional hazards model. RESULTS: In the present study, median follow up was 46.5 months. With regard to the 2-year disease free survival rate and the 5-year survival rate, univariate analysis revealed no significant differences in subgroups according to age, histologic type, resection margin, parametrium, lymph-vascular space invasion, depth of invasion and treatment modality. Tumor size (p=0.0024), lymph node metastasis (p=0.0007) and radiation therapy (p=0.0398) significantly affected the 2-year disease free survival rate in univariate analysis. They (TS: p=0.0001, LN: p=0.0023, RTx: p=0.0428) also significantly affected 5-year survival rate in univariate analysis. Tumor size (RR 35.87, CI 2.94-438.26, p=0.01) and lymph node metastasis (RR 16.6, CI 1.36-202.05, p=0.03) affected 5-year survival rate in multivariate analysis. CONCLUSION: In patients with cervical cancer stage IB2 who underwent operation regardless adjuvant radiation therapy, the important independent prognostic factors were tumor size and LN metastasis.

Prognostic factors of stage IB1 cervical cancer treated surgically / 부인종양

OBJECTIVE: To determine pathologic variables associated with disease free interval and overall survival of patients with stage IB1 cervical cancer who underwent radical hysterectomy and pelvic lymph node dissection. METHODS: The records of 91 patients with stage IB1 cervical carcinoma who underwent radical hysterectomy and pelvic lymphadenectomy from 1997 to 2003 at Gil Medical Center were reviewed retrospectively. Clinical and pathologic variables including tumor size, histologic type, involvement of resection margin, parametrium invasion, lymph node metastasis, lymph-vascular space invasion (LVSI), depth of invasion and age were analyzed by the Kaplan-Meier curves and the log-rank test. Independent prognostic factors were determined by Cox's proportional hazards model. RESULTS: Univariate analysis revealed no significant differences in subgroups according to age, tumor size, histologic type and lymph-vascular space invasion (LVSI). However, significant differences in disease free interval were found in subgroups according to lymph node metastasis and depth of invasion. There were significant differences in overall survival in only subgroups according to lymph node metastasis. Multivariate analysis revealed that lymph node metastasis was the only independent significant prognostic factor. CONCLUSION: These results show that lymph node metastasis was the only independent prognostic factor in stage IB1 cervical cancer managed surgically.